Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
A medical syringe and vial with fake coronavirus vaccine in front of the World Health Organization (WHO) logo. Photo Illustration: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images
Top scientists at the World Health Organization on Friday called for more detailed information on a coronavirus vaccine developed by AstraZeneca and the University of Oxford.
Why it matters: Oxford and AstraZeneca have said the vaccine was 90% effective in people who got a half dose followed by a full dose, and 62% effective in people who got two full doses. AstraZeneca has since acknowledged that the smaller dose received by some participants was the result of an error by a contractor, per the New York Times.
- The half-dose version — the one with 90% efficacy — was tested on a group that didn’t include anyone older than 55, leading to questions about reliability of the results.
- AstraZeneca CEO Pascal Soriot told Bloomberg on Thursday the company is likely to start a new global trial to measure how effective the vaccine is.
What they're saying: "What we've seen is a press release. And what is really the next most important step is that the data really needs to be evaluated based on more than a press release," Katherine O'Brien, director of WHO's immunization and vaccines department, said Friday when asked to comment on AstraZeneca's vaccine.
- "So I think it's too early for us to say anything about what we make of the data and what is needed next. What we really see is more than a press release and to really see the data and have a chance to ask the questions that are needed," O'Brien said.
- "We've heard from AstraZeneca that they would like to do a full trial," said Soumya Swaminathan, the WHO's chief scientist, after noting that all available information on the vaccine has so far come from a press release. "And so if we are to explore this hypothesis of having perhaps a better efficacy with a lower dose, then it would need a trial."
Go deeper: Why AstraZeneca's vaccine matters for the developing world